We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 43

Eli Lilly Canada Inc. v. Apotex Inc (2010 FCA 240)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

This was an appeal of the decision of Madame Justice Gauthier (in the Federal Court) who had found that although Lilly met its burden to prove that Apotex infringed eight Lilly process patents related to the manufacture of the antibiotic cefaclor for material imported before June 3, 1998, Lilly failed to do so for the cefaclor imported into Canada after June 3, 1998

Eli Lilly v Apotex, PMNOC proceedings, strattera, October 29, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

Eli Lilly sought an order of prohibition against Apotex until expiry of its patent for atomoxetine (the '735 patent

Apotex loses the war in Canada and the battle in England: UK courts rely on Canadian decision to find Apotex acting unlawfully in cCnada has consequences in eErope

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, United Kingdom
  • -
  • October 13 2011

Servier developed perindopril erbumine (“perindopril”) which is a successful long lasting ACE inhibitor sold under the trade-mark COVERSYL

AstraZeneca v. Novopharm, appeal of decision to strike Statement of Claim

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes to strike AstraZeneca's Statement of Claim

Sandoz Canada v Abbott Laboratories, appeal and cross-appeal of PMNOC decision, Clarithromycin extended-release, June 22, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 26 2010

Sandoz served a notice of allegation ("NOA") upon Abbott and filed an Abbreviated New Drug Submission ("ANDS") with respect to clarithromycin extended-release

Novopharm Limited v. Eli Lilly and Company (2010 FC 915)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

An impeachment action was brought by Novopharm in respect of a patent for STRATTERA alleging obviousness, anticipation, utility and improper selection

Time for change? Potential impact of Canada’s trade negotiations on pharma patents

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this

AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing

Novopharm v Pfizer, motion for interim relief pending appeal, pregabalin, October 5, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

See the earlier decisions in this case in the May 2010 and July 2010 editions of this newsletter

Merck v Apotex, PMNOC proceedings, dorzolamide and timolol, October 22, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

Merck’s patent in this case (the ‘965 patent) covered the co-administration and co-formulation of dorzolamide and timolol (which was sold as COSOPT